Uveitis Clinical Trial
— SAVE-2Official title:
Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis
Verified date | October 2023 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to find out about the safety and effectiveness of two different doses the study drug, sirolimus, administered intravitreally in patients with uveitis. The potential effectiveness of sirolimus can be utilized to control inflammation in uveitis and yet avoid the potential complications that are usually associated with the systemic use of the drug and other immunomodulatory therapies. In this study, the investigators will administer sirolimus inside the eye (intravitreally) in one of two doses (440mcg/mcL or 880mcg/mcL). Local administration of sirolimus to the eye is not expected to have effects on the rest of the body. Therefore, it may offer a safer way than the current methods used to control the inflammation caused by non-infectious uveitis.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Males and females greater than or equal to 12 years of age. 2. Able to give informed consent and attend all study visits. 3. Have diagnosis of uveitis determined by the Investigator to be non-infectious based on the patient's medical history, history of present illness, ocular examination, review of systems, physical examination, and any pertinent laboratory evaluations. 4. Meet the following criteria: - Have active uveitis, defined as having at least 1+ Vitreous Haze and/or at least 1+ Vitreous Cell Count (SUN scale), and: - are receiving no treatment; or - are receiving: - prednisone = 10 mg/day (or equivalent dose of another corticosteroid), or - at least 1 systemic immunosuppressant other than corticosteroids, or - combination of prednisone = 10 mg/day (or equivalent dose of another corticosteroid) and other systemic immunosuppressant. - Have inactive disease, defined as having 0.5+ Vitreous Haze or less and 0.5+ or less Vitreous Cell Count (SUN scale), and: - are receiving: - prednisone <10 mg/day (or equivalent dose of another corticosteroid), or - at least 1 systemic immunosuppressant other than corticosteroids, or - combination of prednisone <10 mg/day (or equivalent dose of another corticosteroid) and other systemic immunosuppressant. - Have posterior, intermediate, or panuveitis; for panuveitis, if an anterior component is present, it must be less than the posterior component. - Sufficient inflammation to require systemic treatment and, based on the Investigator's decision, warrants intravitreal treatment. - Best-corrected ETDRS visual acuity of 20/400 or better (approximately 20 letters) in the study eye. - Best-corrected ETDRS visual acuity of 20/400 or better in the fellow eye (approximately 20 letters). Exclusion Criteria: 1. Patients with bilateral uveitis who are receiving systemic immunosuppressive therapy (e.g., methotrexate, cyclosporine, cyclophosphamide, chlorambucil, mycophenolate mofetil, tacrolimus, or azathioprine) other than prednisone or other corticosteroids for the treatment of uveitis and the uveitis in the fellow eye, in the opinion of the Investigator, cannot be controlled with standard local therapies alone; 2. Any significant ocular disease that could compromise the visual outcome in the study eye. 3. Intravitreal injections (including but not limited to anti-vascular endothelial growth factors 60 days prior to the baseline; 4. Posterior subtenon's or intravitreal injection of steroids 90 days prior to Baseline; 5. Intraocular surgery within 90 days prior to Day 0 in the study eye; 6. Capsulotomy within 30 days prior to Day 0 in the study eye; 7. History of vitreoretinal surgery or scleral buckling within 90 days prior to Day 0 in the study eye; 8. Any ocular surgery (including cataract extraction or capsulotomy) of the study eye anticipated within the first 180 days following Day 0; 9. Intraocular pressure =25 mmHg in the study eye (glaucoma patients maintained on no more than 2 topical medications with IOP <25 mmHg are allowed to participate); 10. Pupillary dilation inadequate for quality fundus photography in the study eye; 11. Media opacity that would limit clinical visualization, intravenous fluorescein angiography (IVFA), or OCT evaluation in the study eye; 12. Presence of any form of ocular malignancy in the study eye, including choroidal melanoma; 13. History of herpetic infection in the study eye or adnexa; 14. Presence of known active or inactive toxoplasmosis in either eye; 15. Ocular or periocular infection in either eye; 16. Participation in other investigational drug or device clinical trials within 30 days prior to Day 0, or planning to participate in other investigational drug or device clinical trials within 180 days following Day 0. This includes both ocular and non-ocular clinical trials. |
Country | Name | City | State |
---|---|---|---|
United States | Stanford University | Palo Alto | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University | Santen Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of uveitic attacks as assessed by vitreous haze and cells. | 6 months | ||
Secondary | Incidence of adverse and serious adverse events | Incidence, frequencey, and severity of adverse events reported during the first 6 months of the study period. | 6 months | |
Secondary | Changes in central retinal thickness | Improvement or worsening of macular edema compared to baseline. Development of macular edema in patients with otherwise normal macualr thickness at baseline | 6 months | |
Secondary | Steroid sparing effect | Proportion of subjects with active uveitis who achieve complete or partial response to sirolimus at month 6 while discontinuing their steroid therapy.
Proportion of subjects with inactive uveitis who maintain quiscent study eyes at month 6 while discontinuing their steroid therapy. |
6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Active, not recruiting |
NCT04704609 -
Imaging Quantification of Inflammation (IQI)
|
||
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Terminated |
NCT02907814 -
Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography
|
N/A | |
Active, not recruiting |
NCT02252328 -
Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients
|
Phase 2/Phase 3 | |
Completed |
NCT04183387 -
Simvastatin in Uveitis
|
Phase 2 | |
Completed |
NCT01983488 -
Clinical Outcome in Uveitis
|
||
Withdrawn |
NCT00499551 -
A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis
|
Phase 1/Phase 2 | |
Completed |
NCT00132691 -
Multicenter Uveitis Steroid Treatment (MUST) Trial
|
Phase 4 | |
Terminated |
NCT00114062 -
Study to Treat Uveitis Associated Macular Edema
|
Phase 2 | |
Completed |
NCT00476593 -
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
|
N/A | |
Completed |
NCT00001867 -
Effect of Pregnancy on Uveitis
|
N/A | |
Completed |
NCT00379275 -
Eye and Immunogenetic Features of Sarcoidosis
|
N/A | |
Active, not recruiting |
NCT03828019 -
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
|
Phase 3 | |
Terminated |
NCT01939691 -
Macular Edema Nepafenac vs. Difluprednate Uveitis Trial
|
Phase 4 | |
Active, not recruiting |
NCT03889860 -
Objective Choroidal Thickness Measurements in Uveitis
|
||
Completed |
NCT00070759 -
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
|
Phase 2 | |
Recruiting |
NCT05486468 -
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
|
Phase 3 | |
Active, not recruiting |
NCT05385757 -
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
|
||
Active, not recruiting |
NCT06260449 -
Different Treatment Approaches of Presumed Trematode-Induced Uveitis
|
N/A |